Satsuma Pharmaceuticals, Inc.

NasdaqGM:STSA Stock Report

Market Cap: US$36.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Satsuma Pharmaceuticals Valuation

Is STSA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of STSA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate STSA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate STSA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STSA?

Key metric: As STSA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for STSA. This is calculated by dividing STSA's market cap by their current book value.
What is STSA's PB Ratio?
PB Ratio1x
BookUS$37.65m
Market CapUS$36.47m

Price to Book Ratio vs Peers

How does STSA's PB Ratio compare to its peers?

The above table shows the PB ratio for STSA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1x
RAIN Rain Oncology
0.7x23.30%US$44.0m
CGTX Cognition Therapeutics
1.6x-35.35%US$20.2m
SLGL Sol-Gel Technologies
0.7xn/aUS$20.8m
BMND.F Biomind Labs
n/an/aUS$54.3m
STSA Satsuma Pharmaceuticals
1x54.74%US$36.5m

Price-To-Book vs Peers: STSA is good value based on its Price-To-Book Ratio (1x) compared to the peer average (3x).

Price to Book Ratio vs Industry

How does STSA's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

16 CompaniesPrice / BookEstimated GrowthMarket Cap
TLRY Tilray Brands
0.2x90.02%US$494.78m
CTXR Citius Pharmaceuticals
0.1x65.47%US$8.34m
UPC Universe Pharmaceuticals
0.05xn/aUS$2.09m
TNFA TNF Pharmaceuticals
0.2xn/aUS$1.91m
STSA 1.0xIndustry Avg. 1.6xNo. of Companies19PB012345+
16 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: STSA is good value based on its Price-To-Book Ratio (1x) compared to the US Pharmaceuticals industry average (1.8x)

Price to Book Ratio vs Fair Ratio

What is STSA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STSA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate STSA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst STSA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
May ’26n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Apr ’26n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Mar ’26n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Feb ’26n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Jan ’26n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Dec ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Nov ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Oct ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Sep ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Aug ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Jul ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Jun ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
May ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Apr ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Mar ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Feb ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Jan ’25n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Dec ’24n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Nov ’24n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Oct ’24n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Sep ’24n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Aug ’24n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Jul ’24n/a
US$2.50
0%
20.00%US$3.00US$2.00n/a2
Jun ’24US$1.07
US$2.50
+133.64%
20.00%US$3.00US$2.00n/a2
May ’24US$1.05
US$2.00
+90.48%
40.83%US$3.00US$1.00n/a3

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/09 12:58
End of Day Share Price 2023/06/07 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Satsuma Pharmaceuticals, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yifan YeCLSA
Evan SeigermanCredit Suisse
Michael DiFioreEvercore ISI